chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Massive headache; Fatigue; sore muscles; Slight fever (99.8); Chills that were so bad that I could not drink out of a water bottle; woke up feeling sore and couldn't get back to sleep/ general body aches; woke up feeling sore and couldn't get back to sleep; Slight nausea; This is a spontaneous report received from a contactable consumer (patient). This is the first of two reports. A 37-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3277) via an unspecified route of administration in right arm on 22Mar2021 at 12:00, (at the age of 37 years) as dose 2, single, for COVID-19 immunisation. Medical history included depression and COVID-19 on unknown dates. The patient had no allergies to medications, food, or other products. The patient received bupropion hydrochloride (WELLBUTRIN) for an unknown indication on unknown dates in two weeks of vaccination. The patient previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3247) via an unspecified route of administration on left arm on 02Mar2021 at 13:45, as a single dose, for COVID-19 immunisation and experienced sore arm and slight fatigue 24hours after vaccination on 03Mar2021. The patient had not received any other vaccines within 4 weeks prior to the vaccine. Post vaccination, the patient had not been tested for COVID-19. On 22Mar2021, about 6 hours after injection, the patient experienced slight nausea. On 23Mar2021 at about 04:00 (16hrs after vaccination) the patient woke up feeling sore and could not get back to sleep. On 23Mar2021 at about 05:00, the patient came down with chills that were so bad that he could not drink out of a water bottle. He put on extra clothes and sat by fire and chills went away in about an hour on 23Mar2021. On 23Mar2021 at 07:00, the patient had massive headache, general body aches, fatigue, sore muscles and slight fever 99.8 (units not specified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the events. The outcome of event chills was recovered and of other events was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Hospital Course:  Patient is a 75 y.o. male patient of MD with history of BPH, who presented to Hospital with constipation and dysuria. See hospital course below.      Discharge Diagnoses:     Sepsis-Resolved possibly due to COVID vs UTI Was on Vanc/cefepime UC negative. BC NGTD. IV antibiotics stopped.  Given IV fluids.  Leukocytosis improved.    AKI due to obstructive uropathy, POA: Urinary retention, POA: BPH with lower urinary tract symptoms: CT abd/pelvis with marked distention of the urinary bladder, likely chronic BUN 38/Cr 1.54 compared to 18/1 at baseline. Creat 2.3 today. Nephrology consult appreciated. Renal functions improved and back to baseline.    Urology saw the pt and inserted foley as the staff was not able to initially.  Repeat US showed resolution of hydronephrosis.  Started Doxazosin avoid tamsulosin due to Hx sulfa allergy.   Per Urology he will likely need an outlet procedure in the near future due to this significant retention episode with renal insult & massive prostatomegaly on imaging.   Pt has Appt with Urology on Friday   V-Tach Noted bursts of V-Tach. Replace K maintain above 4 Mag checked and 2.2. Cardiology consulted. Apprecaite recommendations.  Pt started on BB. ECHO done showed    1. Left ventricular systolic function is normal with an ejection fraction by Biplane Method of Discs of 67 %.   2. Right ventricular size and systolic function are normal.   3. The left ventricular diastolic function is normal.   4. There is mild tricuspid valve regurgitation.   5. There is pulmonary hypertension, estimated right ventricle systolic pressure is 52 mmHg.   6. The proximal ascending aorta is dilated measuring 4.2 cm with an index of 2.0 cm/m2.  Continues to have SVTs. Monitor today and replace K and Mag.    SPECT in the outpatient setting.  If negative, then pursue cardiac MRI as an outpatient. Per cardiology.  Follow further cardiology recommendations.    Cardiology saw the pt and stable for discharge with out pt follow up.    Constipation, POA: Bowel regimen- and now resolved   Covid-19 Virus Positive, POA: Date of onset of symptoms: 12/06/22 Symptoms present on admission: dysuria and constipation with sepsis on presentation to the ED Date of covid positive test: 12/06/22 Vaccination status: vaccinated Imaging: CT abd/pelvis w/o evidence of acute airspace disease in the lung bases Oxygen requirements on admission: room air Current oxygen requirements: room air Medical therapy: not indicated Consultants following: none Anticipated special isolation end date: 12/12/2022 Currently asymptomatic. No indication for therapy.    Left 4th finger Dupuytren's disease: S/p left 4th finger palmar fasciectomy 12/2/2022 Pathology report of palmar fibromatosis.
rosacea reaction rash on face confirmed by dermatologist, burning down arm and hand, rash on shoulder
My father received the vaccine on Friday 3/5/21. He noted that he wasn?t feeling well following the vaccine. On 3/7/21, he passed away from a heart attack.
Chest tightness, chest tingling from mid sternum radiating to throat. Shortness of breath, labored breathing worsened with deep inspiration.
Temperature this am 101.5 ax.  Fine papulare red rash on trunk.
Patient lost consciousness and fell to the floor within 15 minutes of vaccination.  Patient felt nauseous and was transported by EMS to ER.
covid-19 positive; little bit cough; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (covid-19 positive) and COUGH (little bit cough) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Apr-2021, the patient experienced COVID-19 (covid-19 positive) and COUGH (little bit cough). At the time of the report, COVID-19 (covid-19 positive) and COUGH (little bit cough) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Apr-2021, SARS-CoV-2 test positive: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medication was reported.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-077959 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-077959:case for husband
Information has been received from a nurse practitioner (N.P.) concerning a 5 year old male with a soy allergy and no pertinent medical history who on 08-May-2008, was vaccinated SQ with a second dose of VARIVAX (Merck) (lot #659937/1789U). On 09-MAY-2008 the patient developed red blotches on his face after vaccination with VARIVAX (Merck). Medical attention was sought, the patient was seen by the nurse practitioner. No lab diagnostics were performed. The patient is recovering of blotches on his face. Follow-up information has been received on 12-JUN-2008 from a registered nurse (R.N.). She reported that the event was not related to VARIVAX (Merck). Additional information is not expected.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. In 2008, the patient was inoculated with ZOSTAVAX at a family practice as recommended for routine adult health maintenance and for the long-term prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended. On or about 12-JUL-2016, the patient was treated by a physician at the same family practice for the onset of a severe vesicular rash which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
This is a spontaneous report received from a contactable consumer or other non-HCP (patient). A patient (no qualifiers provided) received the 1st dose of BNT162B2 (Comirnaty, batch/lot# unknown), on Mar 23, 2021, single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. The patient developed illness/became really sick (non-serious), with outcome of unknown. Additional information: Patient had the Pfizer vaccine the COVID-19 vaccine on Tuesday. It was the patient's first dose, and has been really sick since Wednesday. The patient believed people didn't really get much of a reaction after the first dose; but people really got sick with the second dose. Patient was concerned and didn't know if this was normal. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
After the patient received her vaccine, she was in the observation area and alerted the RN that she was short of breath, nauseated, ears with burning sensation, cough, congestion and chest tightness.  Patient moved via wheelchair to our observation bay and the Physician of the day, Dr. (Name) was called.  Patient took two puffs of her Albuterol and oral benadryl given by the nurse.  Patient with retching, continuous cough, increased breathing and heart rate.  911 called and vital signs taken, treated with nebulizer and completed EKG.  Transported to (Name) Hospital (patient preference).
Shoulder Injury Related to Vaccine Administration The woman who administered the vaccine injected way too high and into my shoulder (not the deltoid muscle) I immediately felt a shooting pain. As soon as she was done injecting me she went to the cafeteria for lunch (maybe she was rushing?). I asked two other workers there why she injected it so high and if it will be ok and they responded with ?maybe she aimed down and still made it into the muscle, it should be fine.? I could hardly move my arm for days. Now I have a limited range of motion because of the pain, and my shoulder feels very heavy and tight. There is a bruise where she injected into my shoulder and it?s still very hard to lift my arm and it?s been 11 days. When I do lift or move it you can hear clicking/popping sounds and it is very painful.  I believe she injected vaccine into my Bursa. I never had any shoulder pain or issue before this.
Initial report received from a healthcare professional on 06 October 2006. An 11 year old female patient received a first dose of Adacel (lot number unknown), an intramuscular injection, into the left deltoid. The patient had not received any concomitant vaccines. The patient had allergies to dairies, egg, soy and wheat. The patients medical history included asthma and eczema and denies illness at the time of vaccination (03 October 2006). The patient did not have any problems following prior vaccinations. No specific information about prior exposure was provided. On 03 October 2006, within hours after the patient had received Adacel, the patient experienced fatigue, headache, decreased appetite and stomach pains. The patient was seen by a physician. It was not reported if any corrective treatment was given. At the time of this report (06 October 2006), the patient had not recovered.
Patient came to our pharmacy for Meningitis shot and we did not realized that the vaccine was expired until patient was given the shot. Patient condition is "fine, OK" and no reaction.
This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 29-NOV-2018, the patient was vaccinated with an improperly stored dose of VAQTA with lot # R017644 with expiration date on 09-AUG-2019 for prophylaxis (dose and route of administration were not reported). However, no adverse effects were reported. The administered dose of the vaccine experienced an unspecified temperature excursion on an unknown date for an unspecified time. This report was not due to a digital data logger. No product quality complaint was involved.
itchy bumps around the injection site; redness and swelling in two places on and around my left hand; redness and swelling in two places on and around my left hand; Rash; shingles; soreness; tiredness; This is a spontaneous report from a contactable consumer (patient herself). A 45-years-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number and expiration date was not reported) via an unspecified route of administration, administered in Arm Left on 26Mar2021 17:15 (at age of 45-years-old) as DOSE 1, SINGLE for COVID-19 immunization. Patient was not pregnant at the time of vaccination. Medical history included irritable bowel syndrome, food allergy; sensitive to bananas, dairy products, varicella; she have been exposed to chicken pox as a child from an unknown date and unknown if ongoing. Concomitant medications included xylometazoline hydrochloride (NASAL SPRAY II) taken for an unspecified indication. The patient previously took augmentine [amoxicillin;clavulanic acid] and experienced hypersensitivity. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Patient received first Pfizer vaccine on the evening of 26Mar2021. She experienced soreness, tiredness on same day 26Mar2021. On the morning of 27Mar2021, she woke up with itchy bumps around the injection site and down her arm. As well as redness and swelling in two places on and around her left hand. The rash then spread to forearm, left side, small clusters on her right shoulder blade and little spots near both ankles. 5 days later she went to the doctors because the itchiness and the unbearable pain was not letting up. Her doctor treated her for shingles. He prescribed two medications (not specified). Unfortunately, she developed more rashes on right arm, the underside of her bicep and forearm. Her doctor recommended she should get the second shot. It took 13 days for all of it to stop spreading and itching. It was unknown if patient had received any treatment for AEs. Patient did COVID test (Nasal Swab) post vaccination on 18Apr2021 with unknown results. The outcome of all events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pain, swelling at injection site site (Pneumovax) Redness. itching and report of hives  11-9-07 at 6:30pm
a bad headache; a fever of 101.1; This is a spontaneous report from a contactable consumer (patient). A 47-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date were not reported), via an unspecified route of administration on 22Mar2021 (at the age of 47-years-old) as dose 2, single for COVID-19 immunization. Medical history included hypothyroidism and mood disorder. The patient was in excellent health. Concomitant medications included levothyroxine sodium (SYNTHROID) taken for hypothyroidism; bupropion taken for mood disorder. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date were not reported), via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. The patient experienced a bad headache and a fever of 101.1 on 23Mar2021. It was reported that headache lasted for 24 hours. The fever gradually fell throughout the day and returned to normal 98.2 by 6 p.m. Outcome of events was resolved on 24Mar2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
3 blood clots in his neck and brain; He is affected on his left hand side, he gets dizzy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 74 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose of covid vaccine), for COVID-19 Immunization. The following information was reported: THROMBOSIS (medically significant), outcome "recovering", described as "3 blood clots in his neck and brain"; DIZZINESS (non-serious), outcome "recovering", described as "He is affected on his left hand side, he gets dizzy". The patient underwent the following laboratory tests and procedures: investigation: unknown results; it did not, notes: special test to see if blood clots were in his medical and family history. Therapeutic measures were taken as a result of thrombosis by the patients and had him on a blood thinner. The patient doctor advised him that the only thing he can think is that the vaccine caused this to happen to the caller. The lot number for bnt162b2 was not provided and will be requested during follow up.
I had a large rash around the injection site extended down to my elbow very itching and swollen. I contacted my doctor was advised to take Benadryl took 3-4 days to go down. I was put into a hyper episode lasting 2 months to go down to hypo.
Gave private MRV, private VZV, Td. Client should have received MMR, Td, VZV private. Incorrect age for MMRV. Mgr and RN notified immediately. Pt had no adverse effects in the 45 min post vaccine at clinic.
Tiredness; Headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A male patient received bnt162b2 (BNT162B2), administration date 26Apr2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1st), for COVID-19 immunization. The following information was reported: FATIGUE (non-serious), outcome "unknown", described as "Tiredness"; HEADACHE (non-serious), outcome "unknown", described as "Headache".   Additional Context:  This consumer Confirmed that this report was regarding her older son. After reviewing the call recording, this report was in regards to the caller's older son, who caller mentions experienced tiredness and headache. Caller declined to complete a report for her older son, but mentions he went to get his vaccine the same time as his other brothers (who caller completed a full report on, and it was confirmed the suspect product in their reports was the Pfizer COVID vaccine). The caller mentioned herself, her husband, and older son all experienced tiredness and headache. This report is in regards to caller's older son.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021506701 same reporter/drug/AE, different patient
Within 48 hours of receiving nasal mist:  headaches, fever 100-101, stomach pain, sore throat, aches.  Our daughter is one of SIX children ages 10-14 on our BLOCK who had the same symptoms within 24 hours of getting vaccinated.
This spontaneous report was received from a pharmacist referring to a 56 years old female patient. The patient had no known medical history or drug allergy. On 25-MAY-2016 the patient received a dose of ZOSTAVAX (lot # L036823, expired on 24-DEC-2016) 0.65 ml, once, subcutaneously. No concomitant therapy was reported. On an unspecified date of May 2016, after receiving the ZOSTAVAX, the patient experienced a large red itchy spot at the injection site, upper arm swelling, swelling of her ankles and her blood pressure increased, "higher than her normal blood pressure". The patient stated that she applied unspecified alcohol to the injection site for relief. No lab diagnosis was performed. The pharmacist saw the patient on 01-JUN-2016 and all symptoms had resolved. The causality was not reported. The pharmacist had requested a lot check. The pharmacist did not plan to use this specific lot of ZOSTAVAX, until she received the response. This is one of 4 reports from the same reporter. Additional information has been requested.
Initial and follow up information has been received from a nurse practitioner concerning a 14 year old female patient with no known drug allergies, who on 11-SEP-2007, was vaccinated with the first dose of GARDASIL.  On 13-NOV-2007, the patient was vaccinated with the second dose of GARDASIL.  In November 2007, the patient started to report dizziness, headaches, difficulty with memory and unsure if she actually had been doing the things she had been doing or simply just thought of them.  The patient was a dancer and was unable to dance for a while.  The nurse practitioner reported that the patient tried meclizine for the vertigo.  On an unknown date, the patient had a normal brain MRI.  The nurse practitioner reported that the mom felt 90% of her daughter's symptoms resolved by summer 2008.  The patient and the mother declined to received the third dose of GARDASIL.  The events were considered to be disabling.  Additional information has been requested. 11/5/08-ED records received for DOS 8/28/08-MVA-C/O neck pain. X-rays unremarkable of cervical spine. Impression: acute cervical strain11/12/08-records received- Office visit 11/2/07-C/O dizziness and vertigo intermittently for several months and worse past week, also nausea and headache. Photophobia with headache with nausea. Vision changes. Falling at dance class. Visit 11/13/07-received 2nd Gardasil vaccine. C/O dizziness feels like in a fog. Daily headaches, difficulty with memory. Missing school. Physician concerned about possibility of abuse and depression. Visit 10/1/08-C/O sore throat with painful swallowing.
headache, dizziness, hot flashes, nausea/vomiting, stomach pain, soft stool
pt w/URI sx, s/p vax 13DEC94; mom gave APAP x 48 hrs; unsure when pt became febrile; found blue & apneic in bed 16DEC94 early AM; EMT's found in full cardioresp arrest & intubated & initiated CPR; temp on arrival in ER 104.1 p/45 mins dead;
12/01/21 patient presents to ED for "cough, fatigue, fever, & shortness of breath". PMHx of "COPD, CAD, hypertension"
flu like symptoms; This is a spontaneous report from a non-contactable consumer. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 2nd dose, single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient previously took 1st dose of BNT162B2 on an unspecified date for COVID-19 immunisation. The patient (reporter's mother's cardiologist) had a reaction to his second Pfizer shot and on an unspecified date, experienced flu like symptoms for 36 hours. The outcome of the event was recovered on an unspecified date.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Mom reports swelling and inflammation resolved in 2 to 3 days after Antibiotic started.  Seen once at hospital emergency room because of weekend timing.  Patients own M.D. N/A.  Emergency room staff did not know about arthrus reactions.